Ana Terrén Lora, Bruno F Penadés, Sara López Oliva, Sari Arponen, Gülşah Okutan, Guerthy Melissa Sánchez Niño, Ismael San Mauro Martín
{"title":"慢性功能性便秘患者补充益生菌、益生元和合生元:随机、双盲、安慰剂对照试点临床试验。","authors":"Ana Terrén Lora, Bruno F Penadés, Sara López Oliva, Sari Arponen, Gülşah Okutan, Guerthy Melissa Sánchez Niño, Ismael San Mauro Martín","doi":"10.1093/gastro/goae101","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Functional constipation includes a set of gastrointestinal symptoms unexplainable by an identifiable underlying physical cause or pathology. The prevalence of this condition is high and there is a need to develop strategies to reduce it. Probiotics, prebiotics, and synbiotics may be an alternative treatment for chronic functional constipation.</p><p><strong>Methods: </strong>To compare the efficacy of dietary supplementation on symptoms of patients who suffer from chronic functional constipation. An exploratory, randomized, double-blind, placebo-controlled pilot clinical trial was conducted with 74 patients diagnosed with chronic functional constipation who were divided into four treatment groups-Group A: probiotics; Group B: prebiotics; Group C: synbiotics; Group D: placebo. Each patient was treated for 8 weeks. At the beginning and end of treatment, data were collected by administering questionnaires and scales, including the Bristol stool scale, on gastrointestinal symptoms, bowel movements, and sociodemographic and anthropometric characteristics.</p><p><strong>Results: </strong>Stool frequency increased in all four study groups, and greatest difference was observed in the synbiotics group (2.8 ± 1.3 vs. 5.9 ± 2.6; <i>P</i> < 0.001). Stool consistency improved only in the active treatment groups. Based on the evaluation of gastrointestinal symptoms, participants treated with prebiotics, probiotics and synbiotics showed the greatest improvement in abdominal pain (8.28 ± 2.63 vs. 6.56 ± 2.62; <i>P</i> = 0.009), gastroesophageal reflux (4.60 ± 2.66 vs. 3.45 ± 2.42; <i>P</i> = 0.039) and constipation symptoms (13.00 ± 3.97 vs. 8.71 ± 3.35; <i>P</i> = 0.003), respectively. As for quality of life, the main changes were observed in physical health domains, with a placebo effect.</p><p><strong>Conclusions: </strong>The present study provides evidence supporting the efficacy of dietary supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation after 8 weeks of treatment.</p>","PeriodicalId":54275,"journal":{"name":"Gastroenterology Report","volume":"12 ","pages":"goae101"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552633/pdf/","citationCount":"0","resultStr":"{\"title\":\"Supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation: a randomized, double-blind, placebo-controlled pilot clinical trial.\",\"authors\":\"Ana Terrén Lora, Bruno F Penadés, Sara López Oliva, Sari Arponen, Gülşah Okutan, Guerthy Melissa Sánchez Niño, Ismael San Mauro Martín\",\"doi\":\"10.1093/gastro/goae101\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Functional constipation includes a set of gastrointestinal symptoms unexplainable by an identifiable underlying physical cause or pathology. The prevalence of this condition is high and there is a need to develop strategies to reduce it. Probiotics, prebiotics, and synbiotics may be an alternative treatment for chronic functional constipation.</p><p><strong>Methods: </strong>To compare the efficacy of dietary supplementation on symptoms of patients who suffer from chronic functional constipation. An exploratory, randomized, double-blind, placebo-controlled pilot clinical trial was conducted with 74 patients diagnosed with chronic functional constipation who were divided into four treatment groups-Group A: probiotics; Group B: prebiotics; Group C: synbiotics; Group D: placebo. Each patient was treated for 8 weeks. At the beginning and end of treatment, data were collected by administering questionnaires and scales, including the Bristol stool scale, on gastrointestinal symptoms, bowel movements, and sociodemographic and anthropometric characteristics.</p><p><strong>Results: </strong>Stool frequency increased in all four study groups, and greatest difference was observed in the synbiotics group (2.8 ± 1.3 vs. 5.9 ± 2.6; <i>P</i> < 0.001). Stool consistency improved only in the active treatment groups. Based on the evaluation of gastrointestinal symptoms, participants treated with prebiotics, probiotics and synbiotics showed the greatest improvement in abdominal pain (8.28 ± 2.63 vs. 6.56 ± 2.62; <i>P</i> = 0.009), gastroesophageal reflux (4.60 ± 2.66 vs. 3.45 ± 2.42; <i>P</i> = 0.039) and constipation symptoms (13.00 ± 3.97 vs. 8.71 ± 3.35; <i>P</i> = 0.003), respectively. As for quality of life, the main changes were observed in physical health domains, with a placebo effect.</p><p><strong>Conclusions: </strong>The present study provides evidence supporting the efficacy of dietary supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation after 8 weeks of treatment.</p>\",\"PeriodicalId\":54275,\"journal\":{\"name\":\"Gastroenterology Report\",\"volume\":\"12 \",\"pages\":\"goae101\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552633/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology Report\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/gastro/goae101\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology Report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/gastro/goae101","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:功能性便秘包括一系列无法用可识别的潜在生理原因或病理原因解释的胃肠道症状。这种情况的发病率很高,因此有必要制定减少这种情况的策略。益生菌、益生元和合成益生菌可能是治疗慢性功能性便秘的替代疗法:方法:比较膳食补充剂对慢性功能性便秘患者症状的疗效。我们对 74 名被诊断为慢性功能性便秘的患者进行了一项探索性、随机、双盲、安慰剂对照试验性临床试验,这些患者被分为四个治疗组--A 组:益生菌;B 组:益生元;C 组:合成益生菌;D 组:安慰剂。每位患者接受为期 8 周的治疗。在治疗开始和结束时,通过问卷和量表(包括布里斯托尔粪便量表)收集有关胃肠道症状、排便情况、社会人口学和人体测量特征的数据:所有四个研究组的大便次数都有所增加,其中益生菌组(2.8 ± 1.3 vs. 5.9 ± 2.6; P P = 0.009)、胃食管反流组(4.60 ± 2.66 vs. 3.45 ± 2.42; P = 0.039)和便秘症状组(13.00 ± 3.97 vs. 8.71 ± 3.35; P = 0.003)的差异最大。至于生活质量,主要的变化出现在身体健康领域,并有安慰剂效应:本研究为慢性功能性便秘患者在接受 8 周治疗后补充益生菌、益生元和合成益生菌的疗效提供了证据支持。
Supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation: a randomized, double-blind, placebo-controlled pilot clinical trial.
Background: Functional constipation includes a set of gastrointestinal symptoms unexplainable by an identifiable underlying physical cause or pathology. The prevalence of this condition is high and there is a need to develop strategies to reduce it. Probiotics, prebiotics, and synbiotics may be an alternative treatment for chronic functional constipation.
Methods: To compare the efficacy of dietary supplementation on symptoms of patients who suffer from chronic functional constipation. An exploratory, randomized, double-blind, placebo-controlled pilot clinical trial was conducted with 74 patients diagnosed with chronic functional constipation who were divided into four treatment groups-Group A: probiotics; Group B: prebiotics; Group C: synbiotics; Group D: placebo. Each patient was treated for 8 weeks. At the beginning and end of treatment, data were collected by administering questionnaires and scales, including the Bristol stool scale, on gastrointestinal symptoms, bowel movements, and sociodemographic and anthropometric characteristics.
Results: Stool frequency increased in all four study groups, and greatest difference was observed in the synbiotics group (2.8 ± 1.3 vs. 5.9 ± 2.6; P < 0.001). Stool consistency improved only in the active treatment groups. Based on the evaluation of gastrointestinal symptoms, participants treated with prebiotics, probiotics and synbiotics showed the greatest improvement in abdominal pain (8.28 ± 2.63 vs. 6.56 ± 2.62; P = 0.009), gastroesophageal reflux (4.60 ± 2.66 vs. 3.45 ± 2.42; P = 0.039) and constipation symptoms (13.00 ± 3.97 vs. 8.71 ± 3.35; P = 0.003), respectively. As for quality of life, the main changes were observed in physical health domains, with a placebo effect.
Conclusions: The present study provides evidence supporting the efficacy of dietary supplementation with probiotics, prebiotics, and synbiotics in patients with chronic functional constipation after 8 weeks of treatment.
期刊介绍:
Gastroenterology Report is an international fully open access (OA) online only journal, covering all areas related to gastrointestinal sciences, including studies of the alimentary tract, liver, biliary, pancreas, enteral nutrition and related fields. The journal aims to publish high quality research articles on both basic and clinical gastroenterology, authoritative reviews that bring together new advances in the field, as well as commentaries and highlight pieces that provide expert analysis of topical issues.